Evaluating the effect of bowel preparation plus oral Rifaximin in Brachytherapy for endometrial and cervical Cancer

Evaluating the effect of bowel preparation plus oral Rifaximin on Rectum volume and Dosimetric Parameters in intravaginal High-Dose-Rate Brachytherapy for endometrial and cervical Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200208046412N1

Enrollment

Registered

2020-04-25

Start date

2019-09-21

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Endometrial cancer. Condition 2: Cervical cancer. Malignant neoplasm of endometrium Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention 1: Intervention group: bowel preparation with polyethilenglycol and bisacodyl tablet since 24 hours befor trearment and also rifaximin 400 mg BD since 7 days befor treatment. Intervention

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: pathology based endometrial and cervical cancer doing surgical treatment before brachytherapy correct cylinder insertion

Exclusion criteria

Exclusion criteria: no surgery before brachyhterapy treatment weight above 100 killogram causing not to do MRI

Design outcomes

Primary

Measure	Time frame
Rectal volume. Timepoint: Before(basement) and 7 days after oral Rifaximin. Method of measurement: HDR plus 3.0.8 brachytherapy , treatment planning, Bebig & Ziegler company.;Rectal Dose-volume parameters. Timepoint: Before(basement) and 7 days after oral Rifaximin. Method of measurement: HDR plus 3.0.8 brachytherapy treatment planning, Bebig & Ziegler company.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaezeh Ebrahimian Tabrizi

Ahvaz University of Medical Sciences

ebif1988@gmail.com+98 61 3374 3057

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026